April 12, 2024
ASKA Pharmaceutical said on April 11 that its oral contraceptive drospirenone, also known as LF111, hit the main goal of a domestic PIII clinical study conducted in Japanese women seeking birth control. The drug demonstrated its efficacy by meeting the...read more